Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

por Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Publicado 2018